Why a 95 Percent HPLC Result Doesn’t Always Mean 95 Percent

A curcumin extract labeled 95 percent curcuminoids by HPLC looks precise, but that single number can represent three different analytical realities depending on method. A UV method run at 425 nanometers without a certified standard measures total absorbing pigments and can report 95 percent when true curcuminoid content is closer to 60 to 75 percent. A method using a single curcumin standard against a three-curcuminoid mixture typically overstates the result, landing the true figure closer to 85 to 90 percent. Only a full EP or USP method using individual curcumin, DMC, and BDMC standards against a certified reference mixture produces a genuinely defensible 95 percent figure. The practical question for procurement is not what number appears on the COA, but which method generated it, and whether the supplier is willing to provide the underlying chromatogram and reference standard lot number on request — this single check is often where pharmacopoeia compliance is won or lost on botanical extracts.

What This Costs You If You Skip the Verification

A dossier rejection from an EU Novel Food reviewer or a failed TGA registration check does not just cost the fee for resubmission. It costs the production run already sitting in a warehouse waiting on market clearance, the brand client relationship built on a launch date that just slipped by months, and in the worst cases, a full product recall traced back to a heavy metals panel that was never run to the standard the target market actually required. For an OEM or CDMO, that failure lands on your factory’s record with that client, not just on the supplier’s. Verifying pharmacopoeia compliance before the ingredient enters formulation is materially cheaper than discovering the gap after finished product is already on a shelf or in a warehouse, and that timing is the entire point of building pharmacopoeia compliance into ingredient qualification rather than treating it as an audit-week scramble.

What Tier-One Chinese Suppliers Are Actually Doing

At the top of the supply chain, responsible manufacturers no longer claim compliance with a single standard. They run dual-panel or triple-panel testing because their clients span the US, EU, Australia, and Canada simultaneously. This means ICP-MS speciation covering both total arsenic under USP and inorganic arsenic under Ph. Eur. in the same test run, residual solvent panels referencing ICH Q3C classes alongside Ph. Eur. 5.4 annotation, microbial panels reported in TAMC and TYMC format with organism-level confirmation, and reference standards traceable to either USP or EDQM. This is not yet standard market practice, but it represents the pharmacopoeia compliance baseline any supplier formulating for regulated export markets should be able to provide without hesitation.